TLDR
- Abbott Laboratories CEO Robert B. Ford purchased 18,800 shares on January 23, 2026 for approximately $2 million
- The shares were bought at an average price of $107.1259, with prices ranging from $106.735 to $107.485
- Following the purchase, Ford directly owns 253,305 shares and indirectly holds 216,203 shares through the Ford Family Trust
- The insider purchase comes after Abbott reported disappointing fourth-quarter results that missed analyst expectations
- Multiple investment firms have lowered their price targets for Abbott following weak performance across business segments
Abbott Laboratories Chairman and CEO Robert B. Ford made a substantial purchase of company stock last week. The transaction signals confidence from the top executive following a challenging fourth quarter.
Ford bought 18,800 shares of Abbott on January 23, 2026. The purchase totaled $2,013,966 at a weighted average price of $107.1259 per share.
The price range for these transactions fell between $106.735 and $107.485 per share. The shares were placed into the Ford Family Trust.
After this transaction, Ford’s direct holdings stand at 253,305 shares. The Ford Family Trust now holds 216,203 shares indirectly.
The timing of this purchase is noteworthy. Abbott recently reported fourth-quarter results that fell short of Wall Street expectations.
The company missed revenue targets across multiple business segments. This underperformance has prompted several investment firms to reassess their outlook on the stock.
Analyst Reactions to Recent Performance
UBS maintained its Buy rating but set a price target of $158. The firm acknowledged investor concerns about Abbott’s 2026 organic sales growth guidance.
Bernstein SocGen lowered its price target to $125. The firm cited a surprise sales miss and a slowdown in the continuous glucose monitoring business.
TD Cowen reduced its price target to $137. The firm pointed to the revenue miss and more conservative sales guidance for 2026.
Benchmark kept its Buy rating with a $145 price target. The firm attributed the weak performance to issues in the Nutrition Products segment.
RBC Capital decreased its price target to $135. The firm noted the company’s failure to meet revenue expectations across all segments.
Recent Business Challenges
Abbott’s fourth-quarter performance disappointed on multiple fronts. The company struggled across its diverse portfolio of medical devices and nutritional products.
The continuous glucose monitoring business showed signs of deceleration. This segment had previously been a growth driver for the company.
The Nutrition Products segment faced particular headwinds. These challenges contributed to the overall revenue shortfall.
Earnings figures also came in below analyst estimates. This added to investor concerns about the company’s near-term trajectory.
The company’s 2026 organic sales growth guidance has raised questions among market watchers. Several analysts have expressed caution about the outlook.
Despite the recent headwinds, Ford’s personal investment demonstrates leadership’s belief in the company’s long-term prospects. The $2 million purchase represents a material commitment from the CEO.
The stock purchase represents the latest insider transaction for Ford. His combined direct and indirect holdings now total 469,508 shares following this acquisition.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
